This text reveals the wonderful sensitivity and precision of the SPEAR UltraDetect platform, demonstrated by two SPEAR UltraDetect™ assays concentrating on vital neurological biomarkers: Glial Fibrillary Acidic Protein (GFAP) and Neurofilament-Mild (NF-L).
These assays present ultra-sensitivity with excessive precision, permitting for the dependable identification of refined, clinically related adjustments that different ultra-sensitive platforms regularly miss as a result of their excessive variability.
With impressively low coefficients of variation (CVs) even at low concentrations, SPEAR establishes a brand new customary for analytical efficiency, making it an efficient instrument for early identification and longitudinal investigation of neurological issues.
Introduction
Correct biomarker measurement, combining excessive sensitivity and precision, is vital for neurological analysis and therapeutic functions. Biomarkers like as GFAP, which signifies astrocytic activation, and NF-L, which displays axonal injury, are current at low ranges within the blood early within the illness and may rise regularly over time.1-3
Quantifying these indicators at very low ranges in diseases like Alzheimer’s illness, a number of sclerosis, and stroke permits for higher illness administration and sooner intervention.
This necessitates the detection of low-abundance biomarkers and their consistency and reproducibility throughout time and samples. The flexibility to determine disease-related alterations from assay variability requires excessive precision in biomarker measurements.
Whereas typical ultra-sensitive techniques have enabled novel discoveries, they’ve at all times struggled with assay precision and variability, significantly in blood matrices, the place neurobiomarker concentrations are sometimes a lot decrease than in CSF.
These constraints compromise the correct monitoring of small however vital biomarker variations, that are vital for recognizing early illness alerts, assessing remedy response, and monitoring longitudinal illness improvement.
Successive Proximity Extension Amplification Response (SPEAR) is a homogenous, ultrasensitive immunoassay methodology that addresses the sensitivity limitations and complexity of conventional immunoassays.
SPEAR makes use of a novel two-factor authentication strategy to make sure that amplifiable alerts are solely created via extended co-localization of probes heading in the right direction proteins.
It precisely measures protein biomarkers at attomolar concentrations with as little as 1 µl of diluted pattern, outperforming essentially the most delicate heterogeneous platforms in the marketplace.
SPEAR’s homogeneous nature eliminates nonspecific binding related to solid-phase seize, giving it increased specificity than heterogeneous immunoassay platforms. SPEAR’s process eliminates error-prone wash phases, leading to extraordinarily excessive precision.
SPEAR UltraDetect™ assays, based mostly on this core expertise, present unmatched sensitivity for measuring low-abundance biomarkers whereas sustaining excessive specificity and precision.
SPEAR UltraDetect reads knowledge utilizing customary qPCR instruments, leading to extraordinarily constant outcomes throughout a number of qPCR platforms and codecs. It’s easy to combine into present laboratory settings and affords distinctive scalability.
This text offers outcomes demonstrating the excellent precision of the SPEAR UltraDetect GFAP and NF-L assays, 100 % detectability and quantifiability in wholesome samples, and wonderful settlement with the GFAP and NF-L assessments on the broadly used Simoa platform.
Supplies and strategies
Samples from wholesome donors and diseased people have been obtained from a number of industrial sources, comparable to Precision for Medication and BIOIVT, and examined utilizing SPEAR UltraDetect™ NF-L (merchandise 90004, Spear Bio) and GFAP (merchandise 90010, Spear Bio), in addition to Simoa® NF-Mild® Benefit PLUS (merchandise 104364, Quanterix) and Simoa GFAP Benefit PLUS (merchandise 104619, Quanterix).
SPEAR UltraDetect™ methodology
Samples have been dealt with utilizing the Formulatrix® F.A.S.T™ liquid handler and QInstruments® BioShake® iQ, as instructed by SpearBio. To start, mix 1 µL of probe combine with 1 µL of pattern or calibrator, then incubate for 1 hour.
After incubating 6 µL of response combine for 20 minutes, 12 µL of qPCR combine was added for remaining evaluation. The qPCR findings have been translated to protein concentrations utilizing the SPEARview evaluation software program. (Determine 1).
Determine 1. The total SPEAR UltraDetect Assay workflow. Picture Credit score: Spear Bio
Quanterix Simoa methodology
Samples have been run on the Simoa HD-X Analyzer® in line with the producer’s directions.
To start, 100 µL of pattern or calibrator was blended with 25 µL bead reagent, adopted by washing (3x), addition of 100 µL detection reagent, washing (3x), addition of 100 µL SBG reagent, washing (4x), and addition of fifty µL RGP. Protein measurements have been generated utilizing the Quanterix software program.
Outcomes
Precision
Intra-plate CVs for each GFAP and NF-L have been persistently lower than 10 %, with common CVs of three.0 % and three.2 %, respectively (Determine 1A, 2A), demonstrating larger precision in comparison with beforehand revealed Simoa assays.4,5
Sensitivity
SPEAR UltraDetect detects GFAP and Nf-L at pg/mL (Desk 1), figuring out and quantifying 100 % of wholesome samples, with the bottom endogenous readings throughout all investigated matrices not less than one order of magnitude above the practical LLoQ (Determine 1B, 2B).
This degree of sensitivity implies that baseline and minor however disease-relevant adjustments in GFAP and NF-L could be precisely quantified in a variety of neurology analysis functions.
Concordance
Measurements of GFAP and NF-L from SPEAR UltraDetect and Simoa are extraordinarily constant throughout wholesome and sick samples, with R2 values of 0.941 and 0.996, respectively. (Determine 3).
Desk 1. SPEAR UltraDetectTM NF-L and GFAP Assay specs in EDTA plasma and serum samples. Supply: Spear Bio
* Can be utilized for a number of replicates and biomarker measurements.
Determine 2. Precision and quantifiability of SPEAR UltraDetect GFAP assay. (A) Intra-plate CV plot from a complete of 70 samples, together with matched EDTA plasma (n=15) and serum
(n=15) wholesome controls, amyloid damaging plasma (n=6), and amyloid constructive plasma (n=34). The 20 % CV reference line is marked; (B) Endogenous readings of human EDTA plasma. *Heparin plasma and CSF samples are examined for reference solely. Picture Credit score: Spear Bio
Determine 3. Precision and quantifiability of SPEAR UltraDetect NF-L assay. (A) Intra-plate CV plot from a complete of 34 samples, together with matched EDTA plasma (n=10) and serum
(n=10), and amyotrophic lateral sclerosis (n=14). The 20 % CV reference line is marked; (B) Endogenous studying of human EDTA plasma (n=10), serum (n=10), heparin plasma* (n=10), and CSF* (n=10). Practical LLoQ is indicated as dashed traces. Bars point out the imply with the interquartile vary. *Heparin plasma and CSF samples are examined for reference solely. Picture Credit score: Spear Bio
Determine 4. Assay concordance with Simoa platform. (A) 37 samples, together with matched EDTA plasma (n=15) and serum (n=15) samples from wholesome controls, and seven AD
donors have been measured utilizing SPEAR UltraDetect GFPA and Simoa GFAP Benefit PLUS; (B) 26 plasma samples, together with wholesome controls (n=8), a number of sclerosis (MS, n=6), AD (n=2), progressive supranuclear palsy (PSP, n=3), amyotrophic lateral sclerosis (ALS, n=1), PSP/ALS spiked (n=6), have been measured utilizing SPEAR UltraDetect NF-L and Simoa NF-Mild Benefit PLUS. Picture Credit score: Spear Bio
Dialogue
The outstanding sensitivity and precision of SPEAR UltraDetect, as demonstrated on this article, are vital benefits for detecting early, refined adjustments in neurodegenerative biomarkers.
SPEAR UltraDetect permits researchers to determine GFAP and NF-L at ultralow ranges with excessive precision, permitting them to document the earliest shift in protein biomarker ranges in prodromal and gentle phases of neurological issues.
In scientific analysis, SPEAR UltraDetect’s excessive precision makes it simpler to detect and observe biomarker adjustments as illness progresses or in response to remedy, permitting for highly effective biomarker monitoring in longitudinal research.
SPEAR’s demonstrated mixture of excessive sensitivity, precision, and scalable implementation establishes it as a sport changer for neurology functions starting from early illness identification to remedy improvement.
References
- Wang, X., et al. (2024). Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC medication, 22(1). DOI: 10.1186/s12916-024-03418-8. https://hyperlink.springer.com/article/10.1186/s12916-024-03418-8.
- Samadzadeh, S. and Sleator, R.D. (2025). The position of Neurofilament gentle (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing scientific functions. eNeurologicalSci, [online] 38, p.100550. DOI: 10.1016/j.ensci.2025.100550. https://www.sciencedirect.com/science/article/pii/S2405650225000048?viapercent3Dihub.
- Barro, C., et al. (2022). Serum GFAP and NfL Ranges Differentiate Subsequent Development and Illness Exercise in Sufferers With Progressive A number of Sclerosis. Neuroimmunology and Neuroinflammation, [online] 10(1), pp.e200052–e200052. DOI: 10.1212/nxi.0000000000200052. https://www.neurology.org/doi/10.1212/NXI.0000000000200052.
- Simoa GFAP Benefit PLUS knowledge sheet (obtainable at www.quanterix.com)
- Simoa NF-L Benefit PLUS knowledge sheet (obtainable at www.quanterix.com)
About Spear Bio
Spear Bio is an progressive chief in offering scalable options for ultra-sensitive protein biomarker measurements. Spear Bio’s proprietary expertise, Successive Proximity Extension Amplification Response (SPEAR), employs a novel 2-factor authentication mechanism to exactly measure protein biomarkers at attomolar degree from sub-microliter pattern quantity. Spear Bio is targeted on leveraging its expertise’s unprecedented sensitivity to rework protein analysis and early illness analysis.
Sponsored Content material Coverage: Information-Medical.web publishes articles and associated content material which may be derived from sources the place now we have present industrial relationships, offered such content material provides worth to the core editorial ethos of Information-Medical.web, which is to teach and inform web site guests inquisitive about medical analysis, science, medical units and coverings.
